Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Clin Nucl Med. 2015 Mar;40(3):e196–e200. doi: 10.1097/RLU.0000000000000691

Table 1.

Patient Characteristics

Variable Level Total
N=39 (%)
HPV
Negative
N=21 (%)
HPV Positive
N=18 (%)
P-value*
Sex Female 11 (28.2) 9 (42.86) 2 (11.11) 0.028
Male 28 (71.8) 12 (57.14) 16 (88.89)
Smoking No 18 (46.2) 8 (38.1) 10 (55.56) 0.276
Yes 21 (53.8) 13 (61.9) 8 (44.44)
Alcohol No 28 (71.8) 14 (66.67) 14 (77.78) 0.442
Yes 11 (28.2) 7 (33.33) 4 (22.22)
AJCC Stage 2–3 8 (20.5) 6 (28.57) 2 (11.11) 0.247
4 31 (79.5) 15 (71.43) 16 (88.89)
T Stage T1/T2 20 (51.3) 9 (42.86) 11 (61.11) 0.256
T3/T4 19 (48.7) 12 (57.14) 7 (38.89)
N Stage N0/N1 13 (33.3) 12 (57.14) 1 (5.56) <.001
N2 26 (66.7) 9 (42.86) 17 (94.44)
Tumor Site Oropharynx 22 (56.4) 4 (19.05) 18 (100) <.001
Oral Cavity 17 (43.6) 17 (80.95) 0 (0)
Age Mean (SD) 63.95 (10.3) 68.29 (9.97) 58.89 (8.45) 0.003
*

The p-value is calculated by chi-square test or Fisher's exact test for categorical covariates, where appropriate; and analysis of variance (ANOVA) for age.

HPV, human papillomavirus; AJCC, American Joint Committee on Cancer; SD, standard deviation.